Refractory Pembrolizumab-Induced Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome With Concurrent Hepatitis and Thyroiditis in Endometrial Carcinoma: A Case Report
Abstract
Immune checkpoint inhibitors (ICIs) have transformed oncologic care but can trigger a spectrum of immune-related adverse events. The triad of myocarditis, myositis, and myasthenia gravis, termed MMM overlap syndrome, is a rare but life-threatening complication. Reports have predominantly involved melanoma and lung cancer; cases of endometrial carcinoma have rarely been described. A 77-year-old woman with stage IV serous endometrial carcinoma presented 24 days after a single dose of carboplatin, paclitaxel, and pembrolizumab, with progressive weakness, ptosis, diplopia, and respiratory compromise. Initial evaluation revealed creatine kinase (CK) of 13,000 IU/L, peak high-sensitivity troponin I of 15,000 ng/L, a new right bundle branch block (RBBB) with intermittent high-degree atrioventricular (AV) block, transaminitis, and thyrotoxicosis, indicating concurrent four-organ toxicity. Acetylcholine receptor (AChR), MuSK, and LRP4 antibodies were all negative, consistent with seronegative ICI-induced myasthenia gravis. She was treated with pulse corticosteroids and plasma exchange (PLEX), with rituximab added after the second session for an inadequate response. Persistent myocarditis with sustained troponin elevation prompted further escalation to abatacept and ruxolitinib. Symptoms and serum biomarkers subsequently improved, and she was discharged on continued corticosteroids and ruxolitinib with a planned graded taper. To our knowledge, this is the second reported case of MMM…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.